MedTrace Logo

Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

NCT01023711 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2015-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.

Conditions

Interventions

BIOLOGICAL

Inactivated H1N1 vaccine

0.5 ml IM into Deltoid region of arm

BIOLOGICAL

Inactivated H1N1 vaccine

0.5 mL IM X 1 dose

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • John J. Treanor, M.D. · University of Rochester

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-11-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01023711 on ClinicalTrials.gov